Michael J. Holtzman, MD, the Selma and Herman Seldin Professor of Medicine and director of the Division of Pulmonary and Critical Care Medicine at the Washington University School of Medicine in St. Louis, received a $2.5 million grant from the U.S. Department of Defense for research titled “Preclinical development of a new kinase inhibitor for postviral lung disease.”
The novel drug being developed blocks a molecule that drives the inflammation and damaging lung cell overgrowth that can be triggered after common respiratory viral infections.
Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.